RS groups
RS, tumors, low RS
RECURRENCE, TUMORS, GROUP B
Patients were pooled and grouped based on RS result: RS < 11 (18.0% Emory and 20.3% VCU), RS 11–24 (Emory) or 25 (VCU) (36.0% Emory and 55.9% VCU), and RS 25 (Emory) or 26 (VCU) or higher (46.0% Emory and 23.7% VCU). Patients in Group A were older (median 64 years vs 59 years in Group D), with a higher percentage of low-grade tumors (47.6% grade 1 vs 5.4% grade 1 among RS > 24/25 in Group D). Patients with high RS result (Group D) had a higher percentage of nodal involvement (48.6%) than those with low RS result (23.8% in Group A). Nodal involvement among randomized patients with intermediate RS results differed somewhat, with 22.2% N + in Group B and 37.5% N + in Group C. Results are summarized in Table Demographic and clinical characteristics by treatment group(a) Nonparametric testing was used for Group A = Recurrence Score < 11, Group B = Recurrence Score 11–24 (Emory study) or 11–25 (VCU study) receiving NHT, Group C = Recurrence score 11–24 (Emory study) or 11–25 (VCU study) receiving NCT, and Group D = Recurrence score > 24 (Emory study) or > 25 (VCU study)Among patients with high RS result in group D, 2 Emory patients (8.7%) achieved cCR versus 4 patients (28.6%) in the VCU group (